News
Highly positive FM71 Phase 3 Study Results with all primary and secondary endpoints achieved, MED3000 remains on track to obtain US FDA marketing authorisation
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces positive results from the confirmatory Phase 3 clinical study, “FM71” for MED3000 for the treatment of erectile dysfunction (“ED”).
Novo Holdings leads US$50 million investment in South Asia–based MedGenome
Novo Holdings A/S (“Novo Holdings” and “NH”), a leading international investor in healthcare and life sciences, today announces it has led a $50 million investment into MedGenome, a leading genetic diagnostics, research and data company, alongside its existing investors, LeapFrog Investments and Sofina.
Novo Holdings portfolio company Bactolife receives new funding to advance lifesaving protein technology
Bactolife today announced that the Bill & Melinda Gates Foundation has committed, in alignment with the foundation’s charitable mission, an investment of USD 5 million in the company to advance the company’s mission of developing effective and affordable food and feed ingredients to combat gut health issues worldwide.
Alexandra Clyde appointed to Sequana Medical Board of Directors
Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces the appointment of Alexandra Clyde as an independent Non-Executive Director of the Company.
Verona Pharma strengthens commercialization leadership team
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, continues its preparation for commercialization with appointments of Matthew Casbon, Vice President of Sales, Marketing and Training, and Matthew Rysavy, Vice President of Market Access and Trade.
BII announces new Venture House program and initial intake of four innovative companies
BII announces that four companies have joined its new Venture House program. Formerly known as Creation House, the new Venture House program consists of the same 18-month long program with a risk-free convertible loan of EUR 1.3 million.
BII supports three international start-ups developing pioneering science in the therapeutics and health tech space
BII today announces its investment into three international start-up companies from the UK, Germany, and Finland.
Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its development partner, Nuance Pharma, has received clearance from the Center of Drug Evaluation (“CDE”) for its Investigational New Drug (“IND”) application to conduct both Phase 1 and Phase 3 studies with ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”) in mainland China.
Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announced today the closing of its upsized public offering of 14,260,000 American Depositary Shares (“ADSs”), each representing eight ordinary shares of Verona Pharma, nominal value £0.05 per share, at a price to the public of $10.50 per ADS, which includes the exercise in full by the underwriters of their option to purchase an additional 1,860,000 ADSs.
Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering
LONDON and RALEIGH, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Verona…
Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Ensifentrine met primary and secondary endpoints of evaluating…
Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD
Statistically significant improvements in key measures of lung…
F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofim
New Investment from Forbion and Sofinnova Partners
MANCHESTER,…
NeoPhore Enters Three Year Research Collaboration with World Leading Oncologist’s Lab at Major US Cancer Center
Cambridge, UK, 28 July 2022, – NeoPhore Limited, a small molecule…
Versameb to present at the BIO Asia-Taiwan Conference
Versameb AG (“Versameb”), a pre-clinical stage company focused…
Vicebio launched by medicxi to advance the Molecular Clamp technology and develop next generation RSV vaccine
Focused on delivering highly effective vaccines against life-threatening…
Doug Kohrs appointed to Sequana Medical Board of Directors
Highly experienced US medtech leader brings more than 40 years’…
Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update
DSR (Direct Sodium Removal) heart failure drug development:
…
Destiny Pharma announces positive update from US FDA on XF-73 Phase 3 development plans
FDA clarifies Phase 3 and US registration pathway for XF-73…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
